Thinking about what to do with Eli Lilly shares? You’re certainly not alone. The stock has been climbing the leaderboard for ...

Labcorp plans to offer Roche’s recently FDA-cleared blood test to assess early signs of Alzheimer’s disease and other causes ...

CHMP recommends Lilly's donanemab for early Alzheimer's in ApoE4 heterozygotes or non-carriers. TRAILBLAZER-ALZ trials show donanemab slowed cognitive decline and reduced disease progression risk. Get ...

New blood tests could help doctors diagnose Alzheimer's disease faster and more accurately, researchers reported Sunday – but ...

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having completed treatment Data underscores the ...

Eli Lilly has cleared a major hurdle in its bid to win European approval for its Alzheimer's disease drug Kisunla. Eli Lilly on Friday said the European Medicines Agency's Committee for Medicinal ...

Eli Lilly & Company (NYSE:LLY) ranks among the stocks to benefit from an onshoring boom. On July 22, BMO Capital reaffirmed its $900 price target and Outperform rating for Eli Lilly & Company ...

The EU medicines regulator on Friday rejected Eli Lilly's (LLY.N), opens new tab Alzheimer's drug, saying the treatment's ability to slow cognitive decline was not large enough to outweigh the risk of ...

Julianne Moore had an important message for people watching the World Series this week, and I was one of them. Maybe you saw it, too?

Fresh off launching a national ad campaign to promote its Alzheimer’s treatment Kisunla, Eli Lilly is unveiling another effort focused on brain health — with some celebrity support. In 2015, Julianne ...

Get the latest on Novo Nordisk's Alzheimer's trial, stock outlook, and market risks. See what investors need to know before ...